Albumin-bound paclitaxel augment temozolomide treatment sensitivity of glioblastoma cells by disrupting DNA damage repair and promoting ferroptosis

BACKGROUND: Temozolomide (TMZ) treatment efficacy in glioblastoma (GBM) patients has been limited by resistance in the clinic. Currently, there are no clinically proven therapeutic options available to restore TMZ treatment sensitivity. Here, we investigated the potential of albumin-bound paclitaxel...

Descripción completa

Detalles Bibliográficos
Autores principales: Qu, Shanqiang, Qi, Songtao, Zhang, Huayang, Li, Zhiyong, Wang, Kaicheng, Zhu, Taichen, Ye, Rongxu, Zhang, Wanghao, Huang, Guanglong, Yi, Guo-zhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10612313/
https://www.ncbi.nlm.nih.gov/pubmed/37891669
http://dx.doi.org/10.1186/s13046-023-02843-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10612313/
https://www.ncbi.nlm.nih.gov/pubmed/37891669
http://dx.doi.org/10.1186/s13046-023-02843-6

Ejemplares similares